Initial Antibiotic Treatment for Lactose-Fermenting Gram-Negative Rods

Risk Stratification Determines Initial Therapy

The Infectious Diseases Society of America recommends that patients who are critically ill, septic, neutropenic, have femoral catheters, or have known gram-negative infection foci should receive empirical broad-spectrum antibiotic therapy immediately 1, 2, 3
For patients with recent colonization or infection with multidrug-resistant (MDR) gram-negative pathogens, the Infectious Diseases Society of America suggests initiating dual-agent therapy with two different antimicrobial classes 1, 2, 3, 4
Risk factors for MDR organisms include prior antibiotic therapy within 90 days, hospitalization >2 days in past 90 days, healthcare-associated infections, poor functional status, hemodialysis, and immunosuppression 5

For community-acquired infections in non-critically ill patients without MDR risk factors, fluoroquinolones (ciprofloxacin) are effective but should be reserved for beta-lactam allergies due to rising resistance 6
For critically ill or MDR-risk patients, carbapenems (imipenem, meropenem, ertapenem) are preferred for ESBL-producing organisms 4, 6, 7, 8
Piperacillin-tazobactam offers broad coverage but has inferior outcomes versus carbapenems for ESBL producers even when susceptible in vitro 4, 8, 9

The Infectious Diseases Society of America recommends that once culture and susceptibility results are available, immediately de-escalate to the narrowest-spectrum single agent 1, 2, 3, 4, 11
Rapid diagnostic tests (MALDI-TOF, PCR panels) should be utilized to reduce time to appropriate therapy by >15 hours 11
De-escalation reduces mortality in ICU patients, minimizes selective pressure for resistance, and decreases collateral damage to normal flora 5, 6

Standard treatment duration is 7-14 days for uncomplicated infections 2, 3, 9
For catheter-related bloodstream infections, remove short-term catheters immediately and consider removing long-term catheters with persistent bacteremia >72 hours despite appropriate antibiotics 1, 2, 4, 8, 9

Do not use cephalosporins routinely in settings with high ESBL prevalence—their overuse drives resistance 6
Avoid fluoroquinolones as first-line empirical therapy—resistance rates in E. coli have risen substantially, and they exert selective pressure for ESBL-producing Enterobacteriaceae and MRSA 6
Do not continue broad-spectrum empirical regimens beyond 24-48 hours without microbiological justification—failure to de-escalate increases mortality and resistance 5, 6, 11